PowerPoint Presentation

Lee Boulden

✖
PDF IR Presentation Q4 FY20 vfinal 
INVESTOR P R E S E N TAT I O N
September 2020

Disclaimer
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information contained in this presentation constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this presentation that are not statements of historical fact may be deemed to be forward-looking statements. Forward looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "potential", "believe", "intend" or the negative of these terms and similar expressions. Forwardlooking statements in this presentation include, but are not limited to, statements with respect to accretive earnings, statements with respect to the funded production capacity which may not be achieved or realized within the time frames stated or at all, the anticipated size and or revenue associated with the adult consumer market in Canada and the global market for medical cannabis. Forward-looking statements are based on certain opinions, estimates and assumptions of Aurora's management in light of management's experience and perception of historical trends, current conditions and expected developments at the time the statements are made, including expected growth, results of operations, performance, industry trends and conditions, the current and future regulatory environment and growth opportunities. While Aurora considers these assumptions to be reasonable, based on information currently available, they may prove to be incorrect. Recipients are cautioned not to place undue reliance on forward-looking statements contained herein. Forward-looking statements also necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; future legislative and regulatory developments, including changes in laws; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; the early stage of the cannabis industry in Canada generally and the CBD market in the U.S.; realization of funded production estimates; changes in tax treatment; the ability of Aurora to implement its business strategies; competition; product demand; changes in prices of required commodities; currency and interest rate fluctuations; the risk of difficulties in the integration of Aurora and Reliva; the effects of and responses to the COVID-19 pandemic; the estimated size of the adult consumer market for cannabis in Canada and CBD in the U.S.; the estimated size of the global medical cannabis market; and other risks and uncertainties set out under the heading "Risk Factors" in (i) Aurora's annual information form dated September 10, 2019 and filed with Canadian securities regulators available on Aurora's issuer profile on SEDAR at www.sedar.com and filed with and available on the SEC's website at www.edgar.gov and (ii) Aurora's prospectus supplement dated April 15, 2020 to its short form base shelf prospectus dated May 10, 2019.
Recipients are cautioned that the foregoing risks are not exhaustive and other factors could also adversely affect Aurora and its business and operations. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
Forward-looking statements contained in this presentation are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof, and thus are subject to change thereafter. Aurora disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
No securities of Aurora any kind are being offered as part of this presentation. Before making an investment of any kind in securities of Aurora, potential investors are urged to read Aurora's public disclosure materials filed under Aurora's issuer profile on SEDAR at www.sedar.com and filed with and available on the SEC's website at www.edgar.gov.
2

Defining the Future of Cannabis Worldwide
Aurora Cannabis is a leading licensed producer of cannabis products, leveraging cutting edge technologies to provide premium, innovative products to patients and consumers globally.
Establishing a strong leadership position in three distinct, rapidly growing markets.
3

Earning Our Leadership Position in a ~$200 Billion1 Industry
Leveraging our unique competitive advantages to capture market share

Low Cost Cultivation

Scale & Global Reach

Canadian Market Leadership

IP & Clinical Science
1. Source: BMO Research and Deloitte

Innovative Product Development

Patient Advocacy
4

Cultivation: Our High Margin Strategy
High Quality · Purpose built for cannabis production · Optimized yields · Precision environmental controls · Pharma-grade production · Built to EU GMP specifications Low Cost · Highly automated Mass Scale · Achieving economies of scale · Current run rate 150,000 kg/year
5

Current Production Facilities in Operation

1. AURORA SKY
CAPACITY: >100,000KG/YEAR

2. AURORA RIVER
CAPACITY: 28,000 KG/YEAR EU GMP Certified

3. AURORA NORDIC 1

4. WHISTLER PEMBERTON

CAPACITY: 10,000 KG/YEAR EU GMP Certification Pending

CAPACITY: >4,500 KG/YEAR

Current Annual Production Capacity
142,500 kg/year

· On June 23, 2020, Aurora announced the planned closure of several Canadian production sites to further extract efficiencies from the business and streamline operations
6

Canadian Market Leadership
4 Canadian Cannabis Awards
· Top Sativa Flower · Top Indica Flower · Top Cannabis Spray · Top Balanced Bottle Oil
Top 3 Best-selling Products in Ontario
· Pink Kush · Blue Dream · Tangerine Dream
More than 85,000 active registered
medical patients

10,000 ft2 Flagship Retail Location
West Edmonton Mall, North America's largest mall
7

A Diverse Portfolio of Contemporary Consumer Brands
8

Advancing Cannabis Science & Product Innovation

Science and innovation strategy to harness cannabinoid technologies to commercialize products across a variety of consumer sectors focused on:
· Novel cultivars with unique consumer and agronomic traits · Product innovation · Consumer insights · Cultivation technologies for improved quality and reduced costs
of production

Rights to Over 100 Patents
And Patent Applications ­ Areas Include:
Extraction & Production Systems & Methods
Genetics & Biosynthesis
Horticultural Methods & Apparatus Medical & Recreational Products
Plant variety protection

9

Market Leading Product Development

Enhancing patient and consumer experiences through new innovative product formats

Softgel Capsules

Oral Spray

THC and CBD oils

Vape Pens
10

Where We're Going: Cannabis 2.0
QUALITY EXTRACTS | PROPRIETARY EXTRACTION | SUPERIOR PRODUCTS | SCALE & EXPERTISE
23 SKUs
Launched in December 2019
Initial product categories include vapes, gummies, chocolates, baked goods and mints
11

Core Strategic Objective Achieved: U.S. Market Entry
Carefully executed market entry in the U.S. aligned with Aurora's larger corporate objectives · Large and growing addressable market · Asset-light business model that is highly scalable and has already achieved profitability · Aligned cultures focused on quality, testing and regulatory compliance · Top management team with decades of experience in regulated consumer product sales

U.S. CBD Market Size Estimates 2019 & 2022

BDS
$12.3B

Alignment to Aurora's Core
Business

Strong Execution
Team

Brightfield
$5.1B
Statista
$813M
2019 Estimates

Jefferies
$3.5B
2022 Estimates

Consumer/ Customer Data and Insights

Commitment to Quality
12

Senior Management Team
Miguel Martin
Chief Executive Officer

Glen Ibbott
Chief Financial Officer

Allan Cleiren
Chief Operating Officer
Experienced operational executive with nearly three decades leadership
experience at private and public companies

Jillian Swainson
Chief Legal Officer
Former Partner at Brownlee LLP with experience in corporate, commercial, intellectual
property and securities law and providing advisory services in highly regulated industries

Jonathan Page
Chief Science Officer
Globally renowned cannabis scientist. Co-lead of the Canadian team of scientists who first sequenced the cannabis genome. Co-founder of Anandia Labs
13

Board of Directors

Michael Singer Executive Chairman
Former CFO, Clementia Pharmaceuticals Former CFO, Bedrocan Canada Corp.

Miguel Martin Chief Executive Officer, Director
Former CEO, Reliva Experienced CPG executive with Logic and Altria

Lance Friedmann Director
Experienced global CPG executive with Kraft Foods and Mondelez
Michael Detlefsen Director
Experienced corporate finance and strategic advisor to CPG, agribusiness, and financial services companies

Norma Beauchamp Director
Retired President and CEO of Cystic Fibrosis Canada, Director of Acerus Pharmaceuticals
Ronald Funk Director
Deep consulting business experience, former VP Corporate Affairs and Competitive Improvement for Rothmans

Shan Atkins Director
Certified Public Accountant with over 20 years of corporate leadership experience. Served on public company boards, including Shoppers Drug Mart
Adam Szweras Director
Experienced securities lawyer, Founder of US developer of cannabis, hemp oil, and edible products
14

Investor Relations Email: aurora@icrinc.com Website: investor.auroramj.com
Adobe PDF Library 20.12.75